Recombinant collagen type VII - Shire

Drug Profile

Recombinant collagen type VII - Shire

Alternative Names: HGT-DEB001; rC7; Recombinant collagen VII; SHP-608

Latest Information Update: 29 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southern California
  • Developer Shire
  • Class Non-fibrillar collagens
  • Mechanism of Action Collagen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 29 Oct 2015 Preclinical development is ongoing in USA
  • 12 Feb 2013 Lotus Tissue Repair has been acquired by Shire
  • 30 Jun 2011 Recombinant human collagen type VII technology licensed to Lotus Tissue Repair worldwide (ADNM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top